Quality In Vitro Research Services
|
|
- Beverly Montgomery
- 5 years ago
- Views:
Transcription
1 Quality In Vitro Research Services
2 About Vivacell GmbH Vivacell Biotechnology GmbH is a privately owned contract-based research organisation (CRO) that provides specialised in vitro and in vivo models for testing and developing pharmaceutical and phytopharmaceutical compounds. Additional services for clinical trials and marketing studies are offered. VivaCell s preclinical services include standard protocols and protocols adapted to the needs of the customers using a variety of in vitro and in vivo systems. Why Vivacell GmbH? Because VivaCell is combining highly qualified cellular and molecular biology knowledge and expertise in various fields with a focus on natural products. At VivaCell we offer you complete research projects from basic R&D up to pre-clinical research in one hand. Our clients do not have to gather the research data form various CROs. Application In Vitro Test VivaCell s services include standard protocols and protocols adapted to the needs of the customers using a variety of in vitro assays for cosmetic research. Vivacell, the expert in efficacy testing, offers services for a large variety of indications. 1. ANTI - AGING 2. BEAUTY / ESTHETIC 6. SKIN COMFORT 7. PHYTOCHEMISTRY 3. REGENERATION 4. IMMUNOCOSMETIC 5. SKIN PROTECTION 1
3 1. Claim: Anti-Aging Cell Proliferation Cellular Oxidative Stress ORAC (Total Antioxidant activity) Glucose uptake Oxygen uptake Hypoxia Telomerase activity and length of telomeres Tissue Remodeling (ECM proteins) Autophagy Sensory Receptors (anti-wrinkle) /Dermal Fibroblasts Cell-free assay /Fibroblasts /Immune cells Fibroblasts TRPV-1 assays (inhibition) 2. Claim: Beauty/Esthetic Hair Growth Hair Growth (hair loss) Whitening Cell Volume Vasular tone (NO release) Vascular tone (HIF-1 pathway) Human dermal papilla cells In Vitro enzymatic activity Melanocytes Adipocytes Human Dermal Microvascular Cells /Fibroblasts 2
4 3. Claim: Regeneration Cell Proliferation Tissue Remodeling Real-time wound healing Apoptosis Differentiation (Cornification) Cell Metabolism Immunomodulation I Expression of skin differentiation genes Endocannabinoid system /Dermal Fibroblasts Fibroblasts/Adipocytes, Fibroblasts, Fibroblasts, Fibroblast/Adipocytes T Cells, Fibroblasts/Adipocytes 4. Claim: Immunocosmetic Inflammation Immunosenescence Histamine Release Immunomodulation I Immunomodulation II Immunomodulation III Macrophages/Fibroblasts/ Human primary T Cells Mastocytes T Cells Dendritic Cells Dendritic-to-keratinocytes communication 3
5 5. Claim: Skin Protection Cytotoxicity Inflammation I (cytokines and PGs) Inflammation II (NF-kB and STATs) Cellular Oxidative Stress Detoxification (Nrf2 activators) Transepithelial electrical resistance (TEER) Expression of tight junction proteins /Dermal Fibroblasts Dermal cells and Immune cells, Fibroblasts and 3D cultures *Proliferation Low Saturation 4
6 6. Claim: Skin Comfort Inflammation Itching (histamin release inhibition) Sensory receptors (cooling, analgesia...) Macrophages/Fibroblasts/ Mastocytes TRPV-1/TRPA-1/TRPM-8/CB1 7. Claim: Phytochemistry Natural products from medicinal plants, either as pure compounds or as standardized extracts, provide unlimited opportunities for new dermocosmetics because of the unmatched availability of chemical diversity. Therefore, we also provide phytochemistry services to identify the chemical profile of your extracts and to isolate the major bioactive products. We have experience in analytical methodologies, which include the extraction, isolation and characterization of active ingredients in botanicals and herbal preparations. 5
7 In Collaboration with SimCosmetic Biotech SimCosmetic Biotech is a company focused on the development of novel dermocosmetics based on natural products. SimCosmetic Biotech has developed technological platforms for screening and studying the biological activity of potential cosmetics and dermatological products in order to respond to the increasing demand of new dermatological agents with tested mechanism and proven efficacy. In addition we can generate novel products with synergistic activities saving costs and time. Intelligent Solutions for Novel Cosmetic Developments Vivacell s Contact Vivacell Biotechnology GmbH Ferdinand-Porsche-Str. 5 D Denzlingen Germany Dr. Bernd Fiebich (CEO) fiebich@vivacell.de
Epithelial In Vitro Testing
Epithelial In Vitro Testing BLADDER SKIN MAMMARY 2D AGING CO-CULTURE CELLS 3D AIRWAY CORNEA ORAL Standard Tests Tailored Tests Custom Tests Swiss Quality Products www.cellntec.com In Vitro Tests With a
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationINNOVATION ALMOST 180 MILLION EUROS AREAS OF INNOVATION
From health to beauty INNOVATION IMAGINING FUTURE PRODUCTS 40 Investments in R&D reflect the importance that we attach to the discovery and development of innovative therapeutic and well-being solutions,
More informationr&d lab contract manufacturing marketing lab
r&d contract manufacturing marketing Skincare Solutions About us Since 1978, Sinerga is a contract manufacturer and cosmetic ingredients supplier for the cosmetic and dermo-pharmaceutical industry. A multi-skilled
More informationSKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY
SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY COMPANY BACKGROUND Specializes in liquid and semi-solid topical products Rx, OTC & Therapeutic
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationOUR MISSION OUR EXPERTISE OUR SERVICES
Capacités Biotherapeutics Solutions (C.B.S) is a newly created business unit of CAPACITÉS LLC, an affiliate company of the University of Nantes (France). By gathering experts and core facilities, C.B.S
More informationPreclinical development for SSc indications NO COPY. a preclinical portfolio in a perfect world. Jörg Distler
Preclinical development for SSc indications a preclinical portfolio in a perfect world Jörg Distler Department of Internal Medicine 3 and Institute for Clinical Immunology University of Erlangen-Nuremberg
More informationApplications and Development of Organotypic Skin Cultures
Applications and Development of Organotypic Skin Cultures SILVYA STUCHI MARIA-ENGLER CLINICAL CHEMISTRY AND TOXICOLOGY DEPT SCHOOL OF PHARMACEUTICAL SCIENCES UNIVERSITY OF SÃO PAULO Overview Failings of
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationIntroduction to Cosmetic Active Ingredients What place for Marine Biotechnologies?
Introduction to Cosmetic Active Ingredients What place for Marine Biotechnologies? Rémi Laville, Ph.D Ingredients R&D Director Cosmo International Ingredients Marine Biotechnology enabling future innovation
More informationOutcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL
Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo
More informationYOUR OWN LIFE
YOUR OWN LIFE Stromal Tissue (ST), a Regenerative Source There is a worldwide consensus that the isolation and collection of regenerative Mesenchymal Stem Cells (MSC s) from differentiated body tissues
More informationThe main goal of the strategic partnership is the development of innovative, all-natural cosmetic active ingredients and aroma molecules.
PRESS RELEASE Symrise: Strategic partnership with BRAIN and AnalytiCon Discovery (Holzminden/Potsdam/Zwingenberg, April 2, 2007) Symrise GmbH & Co. KG, the world s fourth-largest supplier of fragrance
More informationPROBACILLUS REVIVE. Probiotic + Optimizes Moisturization + Promotes Homeostasis + Exfoliates. Tomorrow s Vision Today!
PROBACILLUS REVIVE Probiotic + Optimizes Moisturization + Promotes Homeostasis + Exfoliates Tomorrow s Vision Today! Probacillus Revive Technical Information: Product Code: 16618 INCI Name: Lactobacillus
More information100% PURE & NATURAL. THE ORIGINAL: only made by bitop
100% PURE & NATURAL. THE ORIGINAL: only made by bitop Ectoin natural is a powerful multifunctional active ingredient with outstanding efficacy. It prevents cell damage and provides repair and regeneration
More informationSHANGHAI MEDICILON INC.
美迪西生物医药 Integrated Preclinical Drug Discovery Services SHANGHAI MEDICILON INC. Company Profile Shanghai Medicilon Inc. is one of the top contract research organizations (CRO) in China. Since its establishment
More informationIntensive skin repair
Intensive skin repair Temporary version 3-7-213 Fast skin healing to erase skin superficial lesions. Erasyal stimulates the three steps of the skin repairing mechanism: control of the inflammatory process
More informationIntegrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation
Integrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation João Barroso 10 th EPAA Annual Conference Brussels, 2014 Conventional Toxicology Chemical Animal model Pancreatic tumor Observe
More informationUse of Adverse Outcome Pathways (AOPs) to reduce uncertainty and animal use in chemical hazard and risk assessment
Use of Adverse Outcome Pathways (AOPs) to reduce uncertainty and animal use in chemical hazard and risk assessment MatTek, Inc. MatTek, Inc. Reinnervate, Inc. Molecular initiating event Intermediate Events
More informationCupron Pillowcases and Eye Masks SAFETY REPORTS
Cupron Ltd. Ligad Center 2, 4 Hama`ayan St., Modiin 71700 P.O.B. 23311, 91233 Jerusalem www.cupron.com Tel: +972.8.3731000 Fax: +972. 8.9267115 Company no.: 511471930 Cupron Pillowcases and Eye Masks SAFETY
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationIK4 BIOTECHNOLOGY & BIOMATERIALS. Research Alliance.
IK4 Research Alliance BIOTECHNOLOGY & BIOMATERIALS www.ik4.es BIOTECHNOLOGY AND BIOMATERIALS, CROSS-CUTTING TECHNOLOGIES The biotechnology and biomaterials fields are characterised by the fact that they
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationBNG 331 Cell-Tissue Material Interactions. Wound Healing I
BNG 331 Cell-Tissue Material Interactions Wound Healing I Course update LBL 4 Friday; paper posted Need a volunteer to switch groups! Much better job on LBL 3 figure summaries BNG spring seminar 3 this
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationPierre Fabre. Company presentation September 7th 2011
Pierre Fabre Company presentation September 7th 2011 Who We Are: A French medium-sized pharmaceutical company looking for partners for research and development of added value, efficient and innovative
More informationBioengineering to reduce animal use and improve drug development
Bioengineering to reduce animal use and improve drug development Anthony Holmes PhD Programme Manager Technology Development NC3Rs Institute of Bioengineering Launch Event Queen Mary, University of London
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationApplication of RNA Interference to Anti-Doping. Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China
Application of RNA Interference to Anti-Doping Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China From Plants to Worms to Humans: Discovery and Mechanism of RNAi Alnylam Pharmaceuticals
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationThe Food and Drug Administration Predictive Toxicology Roadmap and its Implementation
1 The Food and Drug Administration Predictive Toxicology Roadmap and its Implementation Public Hearing Request for Comments Gary Phillips PhD Principal Scientist Limited Guidance Toxicology data from the
More informationNegatively charged microspheres provide an additional surface for cell attachment leading to proliferation, tissue regeneration and wound healing
Negatively charged microspheres provide an additional surface for cell attachment leading to proliferation, tissue regeneration and wound healing Authors: Correa LG, Peter R, Clerici G, Ritter V. 2017
More informationCharacterization of anti-inflammatory substances from Cyanobacterias
Studying the international way Characterization of anti-inflammatory substances from Cyanobacterias Dipl.Biol. Maren Pflüger, Ph.D. 22.06.2016 Cyanobacteria European Territorial Co-operation Czech Academy
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationMyelin Repair Foundation Research Progress Report June 2006-July 2007
Myelin Repair Foundation Research Progress Report June 2006-July 2007 In July 2004, the Myelin Repair Foundation initiated a five-year research plan with the mission of discovering and validating new therapeutic
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationMASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)
MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of
More informationOverview of PhytoCellTec Products
Overview of Products Stem Cell Cosmetic Stem Cell Cosmetic, the New Trend Stem cells are one of the most fascinating areas of modern biology and medicine. This is due to their remarkable characteristics
More informationCONFLUENCE LIFE SCIENCES ACQUISITION
CONFLUENCE LIFE SCIENCES ACQUISITION Dr. Neal Walker President and CEO August 2017 Copyright 2017 Aclaris Therapeutics. All rights reserved. A-1 Disclaimer Any statements contained in this presentation
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More information7th Annual Shanghai Symposium on Clinical and Pharmaceutical Solutions through Analysis
Mechanistic Physiological PhysioPD Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach Sharan A Pagano SVP, Scientific Alliances at Rosa & Co. LLC 7th Annual Shanghai
More informationLooking for clinical trial in dermatology field
Technology Request Summary Looking for clinical trial in dermatology field A French company specialized in cosmetics have patented a new formulation for one of its product. The owner of the company would
More informationSCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]
SCM Lifescience [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea 22332 [Website] http://www.scmlifescience.com COMPANY PROFILE [Industry] SCM Lifescience is a research-based biopharmaceutical company
More informationCombining Target-Based and Phenotypic Discovery Assays for Drug Repurposing. Sharlene Velichko, Ph.D. Director of Research Biology November 11, 2017
Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing Sharlene Velichko, Ph.D. Director of Research Biology November 11, 2017 1 Drug Repurposing Finding new life for old drugs Initial
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationAdding value to Indigenous Knowledge through Scientific Innovation
THE WORLD BANK Adding value to Indigenous Knowledge through Scientific Innovation INTERNATIONAL WORKSHOP ON INDIGENOUS KNOWLEDGE Benoni, South Africa 9-11 February 2005 Marthinus Horak Programme CSIR Bio/Chemtek
More informationStem cell and cell therapeutics research in Lithuania. Bernardas Morkunas Head of Business Development
Stem cell and cell therapeutics research in Lithuania Bernardas Morkunas Head of Business Development Lithuanian biotech Biotechnology is considered as one of 2014-2020 Smart Specialisation priority fields
More informationJuly 4, 2017 Shigenori Ohkawa, Ph.D. Head of Central Pharmaceutical Research Institute
Research and Development at JTʼs Pharmaceutical Business July 4, 2017 Shigenori Ohkawa, Ph.D. Head of Central Pharmaceutical Research Institute FORWARD-LOOKING STATEMENTS This presentation contains forward-looking
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationIntroducing VitroScreen Research Platform
Introducing VitroScreen Research Platform Lorenzo Meloni - Chemist OUR MISSION We are determined to further the scope of biologically relevant, reproducible and predictive in vitro experimental models
More informationSCIENCE OF SOUTHERN SWEDEN
SCIENCE OF SOUTHERN SWEDEN Skåne, in the southernmost part of Sweden, has a long history of pharmaceutical development which has created a strong position for chemistry and formulation science perfectly
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH- TITLE: PRINCIPAL INVESTIGATOR: CONTRACTING ORGANIZATION: REPORT DATE: TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
More informationComvita Innovation Summer Studentship
Comvita Innovation Summer Studentship The following research projects are for 10 week summer positions with Comvita Innovation, which come with a good break over the Christmas/New Year holiday period,
More informationCitrustem. Orange stem cells. Organizes the inner structure of the skin for a younger appearance ANTI-AGING
December 14 Orange stem cells. Organizes the inner structure of the skin for a younger appearance ANTI-AGING » The architect of the skin Stem cells from orange for a sustainable beauty Organizes and redensifies
More informationLondon, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency 1 2 London, 11 October 2006 Doc. Ref. 3 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) 5 DRAFT 6 7 GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY MEDICINAL
More informationv. 0 V-lift in 30 min!
v. 0 V-lift in 30 min! Marine bio-research, more than water Ocean, lifeblood of Earth, has an untapped potential, with only a 5% explored Unique species from the ocean's depths and sea breeze, to the marine
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Jefferies Global Healthcare Conference June 4, 2015 Safe Harbor Statement The statements made in this presentation that are not statements of historical fact are forward looking
More informationChanges to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi
Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodies Office of Biotechnology Products Center for Drug
More informationStem Cell Services. Driving Innovation for Stem Cell Researchers
Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,
More informationWe offer integral tailor-made solutions, providing our expertise, flexibility and capability from early stages to launch.
Reig Jofre www.reigjofre.com Reig Jofre is a pharma company focused on the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements, as well as on contract
More informationRecent years have witnessed an expansion in the disciplines encompassing drug
Course overview Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of Universities
More informationOutline. o Immunogenicity of therapeutic protein aggregates. o Clinical evidence. o Models to study the immunogenicity of aggregates
Immunogenicity of Therapeutic Protein Aggregates Ehab Moussa 11-14-2016 Outline o Immunogenicity of therapeutic protein aggregates o Clinical evidence o Models to study the immunogenicity of aggregates
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationClinical Trials for Biotechnology Medicines
Clinical Trials for Biotechnology Medicines by James A Southern Member of the Clinical Trials Committee of MCC A personal view point August 2007 Bio-Technology 2007 1 Relevant Properties of Biotechnology
More informationDermal Studies at CBI
Dermal Studies at CBI Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA 94085 Telephone: 408.738.9260 www.compbio.com Premier Preclinical Contract Research Organization Over 20 years of experience
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationTHE OECD PROGRAM ON ADVERSE OUTCOME PATHWAYS (AOP)
THE OECD PROGRAM ON ADVERSE OUTCOME PATHWAYS (AOP) WC-9 Satellite meeting AOP 101 24 August 2014 Anne Gourmelon Principal Administrator OECD Test Guidelines Programme Environmental, Health and Safety Division
More informationHealth research and innovation services
Health research and innovation services Health research and innovation services ALIDANS PROVIDES SERVICES AND PRODUCTS FOR RESEARCH AND INNOVATION (R&I) IN THE HEALTH FIELD, THANKS TO A WORLDWIDE NETWORK
More informationEMA s role & responsibility for the development of modern/advanced therapies
EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory
More informationQuality & Safety GLP. 44 q&more 02/14
Quality & Safety GLP 44 q&more 02/14 More than keeping a lab notebook GLP regulations and their new role in the approval of medicines for advanced therapies (ATMPs) Dr Katja Schellenberg, Translation Centre
More informationCorporate Presentation (TWSE 4743) Presented by Dr. Jui-Ching Chen, BD Director
Corporate Presentation (TWSE 4743) Presented by Dr. Jui-Ching Chen, BD Director November 28, 2018 Disclaimer The statements and contents included in this presentation that are not historical in nature
More informationInduction of Hair Growth by Fibroblast-Secreted WNTs. Gail Naughton and Frank Zeigler Histogen, Inc.
Induction of Hair Growth by Fibroblast-Secreted WNTs Gail Naughton and Frank Zeigler Histogen, Inc. Fibroblast Secreted Factors Formed during tissue-engineering manufacturing process by primary human foreskin
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationBIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE
1 BIOTECH OUT-LICENSING OPTIMIZED COMPOUND VALUE Product Oriented Licensing Strategy intilaris LifeSciences Technologiepark Hochbergerstr. 60c CH-4057 Basel Switzerland Phone: +41 61 633 2212 Email: optimize@intilaris.com
More informationProgress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies
Progress and Future Directions in Integrated Systems Toxicology Mary McBride Agilent Technologies 1 Toxicity testing tools of the late 20 th century Patchwork approach to testing dates back to the 1930
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationTopical sirna for management of androgenic alopecia and oily skin Quark Pharmaceuticals, Inc.
Topical sirna for management of androgenic alopecia and oily skin 1 2017 Quark Pharmaceuticals, Inc. About Quark Founded in 1993; privately held Late stage pharmaceutical company with 2 Phase 3 programs,
More informationManual / epics -M H u m a n E p i d e r m i s E q u i v a l e n t w i t h M e l a n o c y t e s
/ H u m a n E p i d e r m i s E q u i v a l e n t w i t h M e l a n o c y t e s CellSysteMS your partner for over 20 years. We focus on primary and stem cells, organotypical 3D tissue models as well as
More informationBreak the 3D barrier CORNING 3D CELL CULTURE
Break the 3D barrier VESSELS SURFACES MEDIA CORNING 3D CELL CULTURE Get there fast with 3D cell culture. Whether you re just getting started in 3D cell culture, looking for proven ways to scale up, or
More informationSome challenges in the development of new toxicity assays using in vitro methods
1 Some challenges in the development of new toxicity assays using in vitro methods J Malcolm Wilkinson, CEO, Kirkstall Ltd. Quasi Vivo - saving lives through better science The challenge: long drug development
More informationBIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials
BIOSCIENTIA Good outcomes are based on good values Central lab services and biomarker analytics for clinical trials BIOSCIENTIA Do you remember when...... US President Ronald Reagan appealed to Michail
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationINTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES.
1 INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES www.lsmuni.lt 2 3 About Lithuanian University of Health Sciences Lithuanian University
More informationNIZO: HOTSPOT FOR MICROBIOME RESEARCH
NIZO: HOTSPOT FOR MICROBIOME RESEARCH Helping you create microbiome modulators Nils Hijlkema, business development manager Personal Care & Pharma 26/03/2018 NIZO for better food & health Independent, private
More informationINDUSTRY S NEEDS FOR 21 ST CENTURY SAFETY SCIENCE & NON-ANIMAL APPROACHES: A UNILEVER PERSPECTIVE
INDUSTRY S NEEDS FOR 21 ST CENTURY SAFETY SCIENCE & NON-ANIMAL APPROACHES: A UNILEVER PERSPECTIVE JULIA FENTEM & GAVIN MAXWELL UNILEVER R&D SAFETY & ENVIRONMENTAL ASSURANCE CENTRE (SEAC) CONTEXT - 1 Our
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationManual / epics -M Human Epidermis Equivalent with Melanocytes
/ H u m a n E p i d e r m i s E q u i v a l e n t w i t h M e l a n o c y t e s CellSystems your partner for over 20 years. We focus on primary and stem cells, organotypical 3D tissue models as well as
More informationABOUT GLYCOSTEM. Company Overview
ABOUT GLYCOSTEM The company is a clinical stage biotech company established in the Netherlands in 2007. The company s headquarters and new state-of-the-art lab and production facilities are based at Pivot
More informationCytomics in Action: Cytokine Network Cytometry
Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University
More informationGenomics Research Center: Current Status & Future Development
Genomics Research Center: Current Status & Future Development Introduction Research in the life sciences has entered a new era after completion of the human genome project and the sequencing of the genomes
More informationCurrent Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)
Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs) Wei Wei Ph.D Center for Drug Evaluation, National Medical Products Administration (CDE,NMPA) 2018/12/04 Tokyo
More informationResearch and Innovation in Drug Discovery and Diagnostics
INTERNATIONAL CONFERENCE Intellectual Property and Health Innovation Challenges for the future April 28, 2014, Athens, Greece Research and Innovation in Drug Discovery and Diagnostics Alexander Pintzas,
More informationBiosimilar mabs Clinical issues Regulatory perspective
Biosimilar mabs Clinical issues Regulatory perspective EMEA Workshop on Biosimilar Monoclonal Antibodies, MD BMWP Chairman European Medicines Agency (EMEA), UK Paul-Ehrlich-Institut, Germany Mechanisms
More information